Recursion Pharmaceuticals Inc Cl A (RXRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -644,759 | -536,637 | -374,384 | -202,487 | -463,661 |
| Depreciation Amortization | 83,701 | 64,223 | 43,180 | 19,331 | 36,494 |
| Accounts receivable | N/A | 33,775 | 30,246 | 4,839 | N/A |
| Accounts payable and accrued liabilities | -2,616 | -7,035 | -1,145 | 3,692 | 6,435 |
| Other Working Capital | 13,688 | 3,005 | 29,301 | -5,852 | -46,758 |
| Other Operating Activity | 178,178 | 116,934 | 64,427 | 48,520 | 108,316 |
| Operating Cash Flow | $-371,808 | $-325,735 | $-208,375 | $-131,957 | $-359,174 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -3,806 | -3,806 | -1,500 | -1,000 | N/A |
| PPE Investments | -6,469 | -5,225 | -4,982 | -1,832 | -13,695 |
| Net Acquisitions | -4,438 | -4,438 | -4,438 | -4,438 | 277,104 |
| Purchase Sale Intangibles | -2,158 | -2,158 | -2,158 | N/A | -3,350 |
| Other Investing Activity | -2,158 | -2,158 | -2,158 | 0 | -3,350 |
| Investing Cash Flow | $-16,871 | $-15,627 | $-13,078 | $-7,270 | $260,059 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -8,425 | -6,258 | -4,131 | -2,047 | -4,440 |
| Common Stock Issued | 528,864 | 395,484 | 141,024 | 41,024 | 300,417 |
| Other Financing Activity | 1,093 | 300 | 1,293 | 1,550 | 8,143 |
| Financing Cash Flow | $521,532 | $389,526 | $138,186 | $40,527 | $304,120 |
| Exchange Rate Effect | 18,044 | 15,957 | 14,088 | 4,833 | -3,406 |
| Beginning Cash Position | 603,024 | 603,024 | 603,024 | 603,024 | 401,425 |
| End Cash Position | 753,921 | 667,145 | 533,845 | 509,157 | 603,024 |
| Net Cash Flow | $150,897 | $64,121 | $-69,179 | $-93,867 | $201,599 |
| Free Cash Flow | |||||
| Operating Cash Flow | -371,808 | -325,735 | -208,375 | -131,957 | -359,174 |
| Capital Expenditure | -6,469 | -5,225 | -4,982 | -1,832 | -13,695 |
| Free Cash Flow | -378,277 | -330,960 | -213,357 | -133,789 | -372,869 |